Squarepoint’s Astria Therapeutics ATXS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-882,792
| Closed | -$11.6M | – | 4257 |
|
|
2025
Q4 | $11.6M | Buy |
882,792
+867,581
| +5,704% | +$10.4M | 0.01% | 1015 |
|
|
2025
Q3 | $111K | Sell |
15,211
-4,651
| -23% | -$31.5K | ﹤0.01% | 4093 |
|
|
2025
Q2 | $106K | Buy |
+19,862
| New | +$96.3K | ﹤0.01% | 4155 |
|
|
2024
Q3 | – | Sell |
-201,210
| Closed | -$1.83M | – | 4098 |
|
|
2024
Q2 | $1.83M | Buy |
+201,210
| New | +$1.96M | ﹤0.01% | 2114 |
|
|
2021
Q3 | – | Sell |
-2,065
| Closed | -$26K | – | 2893 |
|
|
2021
Q2 | $26K | Buy |
+2,065
| New | +$26.8K | ﹤0.01% | 3141 |
|
|
2021
Q1 | – | Sell |
-11,305
| Closed | -$145K | – | 3096 |
|
|
2020
Q4 | $145K | Buy |
+11,305
| New | +$201K | ﹤0.01% | 2623 |
|
|
2020
Q1 | – | Sell |
-2,670
| Closed | -$95K | – | 1855 |
|
|
2019
Q4 | $95K | Buy |
+2,670
| New | +$84.2K | ﹤0.01% | 2353 |
|
Squarepoint's ATXS Position: Q1 2026 in Review
Squarepoint sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 882,792 shares — an estimated $11.6M sold.
Squarepoint first reported a position in ATXS in Q4 2019 and held it in 7 quarters. The position peaked at $11.6M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.
- Squarepoint reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
- Squarepoint sold 882,792 Astria Therapeutics shares in Q1 2026, an estimated $11.6M.
- Squarepoint first reported a position in Astria Therapeutics in Q4 2019 and held it in 7 quarters.
- Squarepoint's Astria Therapeutics position peaked at $11.6M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.